2. Search Result
Search Result
Results for "

Cathepsin+L+Inhibitor

" in MedChemExpress (MCE) Product Catalog:

45

Inhibitors & Agonists

1

Fluorescent Dyes

7

Peptides

1

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-103351
    Cathepsin G Inhibitor I

    		Cathepsin Inflammation/Immunology
    Cathepsin G Inhibitor I (Compound 7) is a potent, selective, reversible, competitive, non-peptidic Cathepsin G inhibitor (IC50 = 53 nM; Ki = 63 nM). Cathepsin G Inhibitor I can be used in research related to immune disorders .
    Cathepsin G Inhibitor I
  • HY-109069
    Petesicatib
    1 Publications Verification

    RO5459072; RG-7625

    		 Cathepsin Inflammation/Immunology
    Petesicatib (RO5459072; RG-7625) is a cathepsin S inhibitor, used in research of immune diseases .
    Petesicatib
  • HY-164729
    FZ-AD005

    		Antibody-Drug Conjugates (ADCs) Topoisomerase Apoptosis Cancer
    FZ-AD005 is a DLL3-targeting antibody-drug conjugate (ADC) with high selectivity, composed of the anti-DLL3 antibody FZ-A038 (HY-P990896), a dipeptide linker (Val-Ala), and DXd (HY-13631D). The Kd value of FZ-AD005 for human DLL3 ranges from 13.29 to 58.3 pmol/L. After binding to DLL3 on the cell surface, FZ-AD005 mediates endocytosis, and the payload DXd is released via cleavage by lysosomal cathepsins. DXd inhibits topoisomerase TopI to induce double-strand DNA breaks, cell cycle arrest and apoptosis, and FZ-AD005 exhibits bystander killing activity against adjacent DLL3-negative cells. FZ-AD005 shows stable circulation in vivo, has good tolerance and acceptable pharmacokinetic profiles in rats and cynomolgus monkeys, and effectively inhibits the growth of DLL3-expressing tumor cells. FZ-AD005 serves as a promising candidate molecule for research on small cell lung cancer and human neuroendocrine prostate cancer .
    FZ-AD005
  • HY-15100
    Balicatib
    2 Publications Verification

    AAE581

    		 Cathepsin Inflammation/Immunology
    Balicatib (AAE581) is a potent, orally active and selective cathepsin K inhibitor with IC50 values of 22, 61, 48, 2900 nM for cathepsin K, cathepsin B, cathepsin L, cathepsin S, respectively. Balicatib inhibits bone turnover, decreases bone formation rates. Balicatib has the potential for the research of osteoporosis .
    Balicatib
  • HY-115733
    Cathepsin L-IN-2
    1 Publications Verification

    (Rac)-Z-Phe-Phe-FMK

    		 Cathepsin Cancer
    Cathepsin L-IN-2 ((Rac)-Z-Phe-Phe-FMK) is an isomer of the Cathepsin L inhibitor Z-Phe-Phe-FMK (HY-141867), with an IC50 of 15 μM for cathepsin L. Z-Phe-Phe-FMK irreversibly blocks the proteolytic function of cathepsins by covalently binding to the cysteine residues in the active center of the enzyme. Cathepsin L-IN-2 and Z-Phe-Phe-FMK can be used to study neurodegenerative diseases (such as GRN-related frontotemporal dementia) and cancer invasion and metastasis.
    Cathepsin L-IN-2
  • HY-146985
    Cathepsin X-IN-1
    1 Publications Verification

    		 Cathepsin Neurological Disease Cancer
    Cathepsin X-IN-1 (compound 25) is a potent Cathepsin X inhibitor with an IC50 of 7.13 µM. Cathepsin X-IN-1 decreases PC-3 cell migration with low cytotoxic .
    Cathepsin X-IN-1
  • HY-100227
    E 64c
    3 Publications Verification

    		 Cathepsin SARS-CoV Metabolic Disease
    E 64c is a derivative of naturally occurring epoxide inhibitor of cysteine proteases, a Calcium-activated neutral protease (CANP) inhibitor and a very weak irreversible cathepsin C inhibitor. E 64c exhibits entry-blocking effect for MERS-CoV.
    E 64c
  • HY-146584
    Cathepsin C-IN-5

    		Cathepsin Inflammation/Immunology
    Cathepsin C-IN-5 (compound SF38) is a potent, selective and orally active Cathepsin C inhibitor with IC50s of 59.9 nM, 4.26 µM, >5 µM, >5 µM, >5 µM for Cat C, Cat L, Cat S, Cat B, Cat K, respectively. Cathepsin C-IN-5 inhibits the Cat C activity in bone marrow and blood. Cathepsin C-IN-5 decreases the activation of NSPs (neutrophil serine proteases). Cathepsin C-IN-5 shows anti-inflammatory activity .
    Cathepsin C-IN-5
  • HY-Y0241
    2-Cyanopyrimidine

    		Cathepsin Metabolic Disease
    2-Cyanopyrimidine is a potent and non-selective cysteine protease cathepsin K inhibitor with an IC50 of 170 nM. 2-Cyanopyrimidine is used for osteoporos .
    2-Cyanopyrimidine
  • HY-148298
    CatD-IN-1

    		Cathepsin Inflammation/Immunology
    CatD-IN-1 (Compound 5) is a Cathepsin D inhibitor with an IC50 of 0.44 μM. CatD-IN-1 holds potential for research in the field of osteoarthritis .
    CatD-IN-1
  • HY-138208
    Z-Phe-Tyr(tBu)-diazomethylketone
    1 Publications Verification

    		 Cathepsin SARS-CoV Infection
    Z-Phe-Tyr(tBu)-diazomethylketone is a potent cathepsin L inhibitor. Z-Phe-Tyr(tBu)-diazomethylketone mediates reovirus disassembly. Z-Phe-Tyr(tBu)-diazomethylketone decreases viral detection .
    Z-Phe-Tyr(tBu)-diazomethylketone
  • HY-108044
    ONO-5334

    		Cathepsin SARS-CoV Metabolic Disease
    ONO-5334 is a potent, selective and orally active cathepsin K inhibitor with Ki values of 0.10 nM, 0.049 nM and 0.85 nM for human, rabbit and rat cathepsin K, respectively. ONO 5334 is an effective antiviral compound against SAR-COV-2 virus activity with an EC50 value of 500 nM. ONO-5334 has the potential for the study of osteoporosis and COVID-19 disease .
    ONO-5334
  • HY-147774
    Cathepsin K inhibitor 6

    		Cathepsin Others
    Cathepsin K inhibitor 6 (compound 19) is an inhibitor of cathepsin K (Cat K) with an IC50 of 17 nM. Cathepsin K inhibitor 6 also has inhibitory effects on other isoforms, with IC50s of 0.05 μM (Cat L) and 0.3 μM (Cat B), respectively .
    Cathepsin K inhibitor 6
  • HY-U00377
    Cathepsin Inhibitor 2

    		Cathepsin Inflammation/Immunology Cancer
    Cathepsin Inhibitor 2 is a potent Cathepsin S inhibitor extracted from patent WO2009123623A1, has a Ki of <20 nM.
    Cathepsin Inhibitor 2
  • HY-P4532
    Ac-Leu-Val-Lys-Aldehyde

    		Cathepsin Neurological Disease
    Ac-Leu-Val-Lys-Aldehyde is a potent cathepsin B inhibitor with IC50s of 4 nM. Ac-Leu-Val-Lys-Aldehyde significantly reduces quinolinic acid (HY-100807)-induced striatal cell death and causes accumulation of LC3-II .
    Ac-Leu-Val-Lys-Aldehyde
  • HY-177315
    Cathepsin K-IN-8

    		Cathepsin Inflammation/Immunology Cancer
    Cathepsin K-IN-8 (cxample 6-60) is a cathepsin K inhibitor that can be used for the study of inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis and tumors .
    Cathepsin K-IN-8
  • HY-112583
    MIV-247

    		Cathepsin Neurological Disease
    MIV-247 is a selective cathepsin S inhibitor with Kis of 2.1, 4.2 and 7.5 nM for human, mouse and cynomolgus monkey cathepsin S, respectively.
    MIV-247
  • HY-N15154
    Tasiamide B

    		Cathepsin HSP Cancer
    Tasiamide B is a Cathepsin D inhibitor, which is a linear peptide found in the marine cyanobacteria Symploca sp.. Tasiamide B is proved as a good template for the development of aspartic proteases inhibitors. Tasiamide B is effective against skin cancer by strongly interacting with the target protein HSP90 .
    Tasiamide B
  • HY-50887
    L-873724

    		Cathepsin Metabolic Disease
    L-873724 is a potent, orally bioavailable, selective and reversible non-basic cathepsin K inhibitor, with IC50s of 0.2, 178, 264, and 5239 nM for cathepsin K, cathepsin S, cathepsin L, cathepsin B, respectively . L-873724 also exhibits an IC50 of 0.5 nM for rabbit cathepsin K. L-873724 inhibits bone resorption .
    L-873724
  • HY-143714
    Cathepsin K inhibitor 2

    		Cathepsin Inflammation/Immunology
    Cathepsin K inhibitor 2 is a potent inhibitor of cathepsin K. Cathepsin K, Cat K is a cysteine protease expressed under the control of CTSK gene and closely related to osteoporosis, whose main function is to hydrolyze collagen. Cathepsin K inhibitor 2 has the potential for the research of osteoarthfitis (extracted from patent WO2021147882A1, compound 78) .
    Cathepsin K inhibitor 2
  • HY-P10118A
    Cathepsin L-IN-3 TFA

    		Cathepsin Others
    Cathepsin L-IN-3 (Compound cat L inh. 7) TFA is selective a noncovalent cathepsin L inhibitor with a Ki of 4.3 nM .
    Cathepsin L-IN-3 TFA
  • HY-113721
    BML-244

    		Cathepsin Inflammation/Immunology
    BML-244 is a potent cathepsin K inhibitor. BML-244 can be used in the study of rheumatoid arthritis (RA) and periodontitis .
    BML-244
  • HY-10290
    MK-0674

    		Cathepsin Metabolic Disease
    MK-0674 is a potent, orally bioavailable and selective cathepsin K inhibitor, with an IC50 of 0.4 nM, shows 1156, 1465, 11857 and 243 fold selectivity over Cat B, Cat F, Cat L and Cat S .
    MK-0674
  • HY-164958
    TB-11

    		Cathepsin Beta-secretase Cancer
    TB-11 is a Cathepsin D inhibitor, with IC50s of 0.126 nM (Cathepsin D), 1.92 nM (Cathepsin E), 48.8 nM (BACE1), respectively. TB-11 can be used for tumor research .
    TB-11
  • HY-123531
    JNJ 10329670

    		Cathepsin Inflammation/Immunology
    JNJ 10329670 is a potent and selective noncovalent cathepsin S inhibitor with a Ki value of 34 nM for human cathepsin S. JNJ 10329670 blocks invariant chain proteolysis in B cells and dendritic cells, as well as antigen-induced T cell proliferation .
    JNJ 10329670
  • HY-163206
    SARS-CoV-2-IN-77

    		Cathepsin SARS-CoV Infection
    SARS-CoV-2-IN-77 (compound 11e) is a cathepsin L and cathepsin S inhibitor with Ki values of 111 nM and 103 nM, respectively. SARS-CoV-2-IN-77 inhibits SARS-CoV-2 with an EC50 value of 38.4 nM in Calu-3 cells without showing cytotoxicity .
    SARS-CoV-2-IN-77
  • HY-P10117
    Cathepsin K inhibitor 5

    		Cathepsin Metabolic Disease
    Cathepsin K inhibitor 5 is a potent Cathepsin K inhibitor .
    Cathepsin K inhibitor 5
  • HY-163842
    Cathepsin K inhibitor 7

    		Cathepsin Inflammation/Immunology
    Cathepsin K inhibitor 7 (compound 7) is a Cathepsin K inhibitor with the pKi of 7.3 aganist CatK. Cathepsin K inhibitor 7 can be used for study of osteoporosis .
    Cathepsin K inhibitor 7
  • HY-151524
    Cathepsin K inhibitor 3

    		Cathepsin Inflammation/Immunology
    Cathepsin K inhibitor 3 (compound 23) is a highly selective cathepsin K inhibitor with an IC50 value of 0.5 nM. Cathepsin K inhibitor 3 has a favorable pharmacokinetic profile and may be used in osteoarthritis (OA) disease studies .
    Cathepsin K inhibitor 3
  • HY-P10061
    Cathepsin K inhibitor 4

    		Cathepsin Cancer
    Cathepsin K inhibitor 4 is a potent carbohydrazide Cathepsin K inhibitor with IC50s of 13 nM, 269 nM, 296 nM for human, rat, mouse Cathepsin K, respectively .
    Cathepsin K inhibitor 4
  • HY-P10065
    RKLLW-NH2

    		Cathepsin Inflammation/Immunology
    RKLLW-NH2 is a Cathepsin L inhibitor .
    RKLLW-NH2
  • HY-105668
    Cathepsin S-IN-1

    		Cathepsin Others
    Cathepsin S-IN-1 (example 1) is a Cathepsin S inhibitor .
    Cathepsin S-IN-1
  • HY-125386
    SQ 32056

    		Cathepsin Cardiovascular Disease
    SQ 32056 is a cathepsin E inhibitor. SQ 32056 can block the pressor response to endothelin .
    SQ 32056
  • HY-P10118
    Cathepsin L-IN-3

    		Cathepsin Others
    Cathepsin L-IN-3 (Compound cat L inh. 7) is selective a noncovalent cathepsin L inhibitor with a Ki of 4.3 nM .
    Cathepsin L-IN-3
  • HY-P0109
    (S,S)-Z-FA-FMK

    		Cathepsin Others
    (S,S)-Z-FA-FMK is a cell-permeable, irreversible cathepsin B inhibitor. (S,S)-Z-FA-FMK blocks LPS-induced production of IL-1α and IL-1β. (S,S)-Z-FA-FMK can be used as a negative control for caspase-1 and caspase-2 inhibitors because it lacks an aspartic acid residue at the P1 position .
    (S,S)-Z-FA-FMK
  • HY-103351R
    Cathepsin G Inhibitor I (Standard)

    		Reference Standards Cathepsin Inflammation/Immunology
    Cathepsin G Inhibitor I (Standard) is the analytical standard of Cathepsin G Inhibitor I (HY-103351). This product is intended for research and analytical applications. Cathepsin G Inhibitor I (compound 7) is an effective, selective, reversible, competitive, non-peptide cathepsin G inhibitor (IC50=53 nM; Ki=63 nM) .
    Cathepsin G Inhibitor I (Standard)
  • HY-15101
    MV061194

    		Cathepsin Metabolic Disease
    MV061194 is a selective cathepsin K inhibitor with a human Ki of 2.5 nM. MV061194 can be used for the research of osteoporosis .
    MV061194
  • HY-Y0241R
    2-Cyanopyrimidine (Standard)

    		Reference Standards Cathepsin Metabolic Disease
    2-Cyanopyrimidine is a potent and non-selective cysteine protease cathepsin K inhibitor with an IC50 of 170 nM. 2-Cyanopyrimidine is used for osteoporos .
    2-Cyanopyrimidine (Standard)
  • HY-177408
    Cathepsin C-IN-7

    		Cathepsin Cancer
    Cathepsin C-IN-7 (Page 68) is a Cathepsin C inhibitor. Cathepsin C-IN-7 can be used in research related to primary cancers and cancer metastases .
    Cathepsin C-IN-7
  • HY-109069R
    Petesicatib (Standard)

    RO5459072 (Standard); RG-7625 (Standard)

    		 Reference Standards Cathepsin Inflammation/Immunology
    Petesicatib (Standard) is the analytical standard of Petesicatib (HY-109069). This product is intended for research and analytical applications. Petesicatib (RO5459072; RG-7625) is a cathepsin S inhibitor, used in research of immune diseases .
    Petesicatib (Standard)
  • HY-171925
    BI-1124

    		Cathepsin Neurological Disease
    BI-1124 is a cathepsin S inhibitor that exhibits simulated sufficient ocular pharmacokinetic-pharmacodynamic coverage in rabbit models via topical ocular administration. BI-1124 can be used for the research of age-related dry eye disease .
    BI-1124
  • HY-183166
    Z-Arg-Lys-AOMK

    		Cathepsin Neurological Disease
    Z-Arg-Lys-AOMK is a cathepsin B inhibitor that can cross the blood-brain barrier. Z-Arg-Lys-AOMK reduces cytosolic cathepsin B activity in homogenates of mouse cerebral cortex and hippocampal tissues, and alleviates motor dysfunction associated with CCI-TBI. Z-Arg-Lys-AOMK can be used in the research of traumatic brain injury .
    Z-Arg-Lys-AOMK
  • HY-179697
    Cathepsin K-IN-9

    		Cathepsin Metabolic Disease
    Cathepsin K-IN-9 is a selective, potent and orally active Cathepsin K inhibitor with an IC50 of 6.2 nM. Cathepsin K-IN-9 has IC50 > 10000 nM for cathepsin B, L, and S, showing over 1600-fold selectivity. Cathepsin K-IN-9 has excellent safety and metabolic stability.Cathepsin K-IN-9 can be used for the research of osteoporosis .
    Cathepsin K-IN-9
  • HY-180799
    Cathepsin L-IN-6

    		Cathepsin Interleukin Related Inflammation/Immunology
    Cathepsin L-IN-6 (Compound 6a) is a selective cathepsin L inhibitor with an IC50 of 0.021 μM. Cathepsin L-IN-6 suppresses cathepsin L activity by directly binding to cathepsin L. Cathepsin L-IN-6 inhibits IL-6 and IL-8. Cathepsin L-IN-6 shows a high anti-inflammatory activity. Cathepsin L-IN-6 can be used in the research of acute lung injury .
    Cathepsin L-IN-6
  • HY-108044R
    ONO-5334 (Standard)

    		Reference Standards Cathepsin SARS-CoV Metabolic Disease
    ONO-5334 (Standard) is the analytical standard of ONO-5334 (HY-108044). This product is intended for research and analytical applications. ONO-5334 is a potent, selective and orally active cathepsin K inhibitor with Ki values of 0.10 nM, 0.049 nM and 0.85 nM for human, rabbit and rat cathepsin K, respectively. ONO 5334 is an effective antiviral compound against SAR-COV-2 virus activity with an EC50 value of 500 nM. ONO-5334 has the potential for the study of osteoporosis and COVID-19 disease .
    ONO-5334 (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: